Showing results (171-180 of 406) with videos related to

Sort By:
Pageof 41
Oncotarget|February 18, 2016
Prognostic relevance of HER2/neu in acute lymphoblastic leukemia and induction of NK cell reactivity against primary ALL blasts by trastuzumabSebastian P Haen, Benjamin J Schmiedel, Kathrin Rothfelder, et al.
Leukemia & Lymphoma|February 12, 2024
Carfilzomib, daratumumab, and dexamethasone (KdD) vs. lenalidomide-sparing pomalidomide-containing triplet regimens for relapsed/refractory multiple myeloma: an indirect treatment comparisonKatja Weisel, Meletios A Dimopoulos, Meral Beksac, et al.
European Spine Journal : Official Publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society|April 26, 2025
Changes in sagittal spinopelvic alignment are associated with increased pain and impaired function in multiple myeloma patientsJulian Kylies, Michael Dirks, Elias Brauneck, et al.
Annals of Hematology|June 18, 2026
Infectious toxicities associated with bispecific antibodies and CAR-T Cells in multiple myeloma: a systematic reviewMagdalena Benda, Patrick Reimann, Wolfgang Willenbacher, et al.
Blood|September 13, 2003
Inhibitory effect of imatinib on normal progenitor cells in vitroKerol Bartolovic, Stefan Balabanov, Ulrike Hartmann, et al.
Onkologie|April 27, 2007
Mitomycin C plus infusional 5-fluorouracil in platinum-refractory gastric adenocarcinoma: an extended multicenter phase II studyJörg Thomas Hartmann, Jan Peter Pintoffl, Salah-Eddin Al-Batran, et al.
Annals of Hematology|September 14, 2014
Prognostic impact of intraocular involvement in primary CNS lymphoma: experience from the G-PCNSL-SG1 trialStephan Kreher, Felicitas Strehlow, Peter Martus, et al.
Transplantation and Cellular Therapy|May 17, 2022
Low Graft Invariant Natural Killer T-Cell Dose Is a Risk Factor for Cytomegalovirus Reactivation After Allogeneic Hematopoietic Cell TransplantationDominik Schneidawind, Silke Duerr-Stoerzer, Sonja Liewer, et al.
Blood Cancer Journal|February 24, 2019
Health-related quality of life in the ENDEAVOR study: carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed/refractory multiple myelomaHeinz Ludwig, Philippe Moreau, Meletios A Dimopoulos, et al.
Bone Marrow Transplantation|May 13, 2026
Experiences and expert panel consensus on bridging therapy before anti-BCMA CAR-T cell therapy in multiple myelomaLeo Rasche, Maria Theresa Krauth, Hermine Agis, et al.
Pageof 41